Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Shares Outstanding (Weighted Average) (2021 - 2025)

Bioventus (BVS) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $66.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 3.21% year-over-year to $66.6 million, compared with a TTM value of $66.6 million through Dec 2025, up 3.21%, and an annual FY2025 reading of $66.6 million, up 3.21% over the prior year.
  • Shares Outstanding (Weighted Average) was $66.6 million for Q4 2025 at Bioventus, roughly flat from $66.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $66.9 million in Q3 2025 and bottomed at $41.8 million in Q2 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $59.4 million, with a median of $62.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) soared 47.06% in 2022, then rose 1.75% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $45.5 million in 2021, then surged by 35.0% to $61.4 million in 2022, then increased by 2.05% to $62.6 million in 2023, then increased by 3.03% to $64.5 million in 2024, then rose by 3.21% to $66.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BVS at $66.6 million in Q4 2025, $66.9 million in Q3 2025, and $66.5 million in Q2 2025.